| Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020 | 5968 | 2020 |
| Air Surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus SWX Ong, YK Tan, PY Chia, TH Lee, OT Ng, MSY Wong | 2981* | |
| Remdesivir for the treatment of Covid-19—preliminary report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1836, 2020 | 2532 | 2020 |
| Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore BE Young, SWX Ong, S Kalimuddin, JG Low, SY Tan, J Loh, OT Ng, ... Jama 323 (15), 1488-1494, 2020 | 2496 | 2020 |
| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 1755 | 2021 |
| Remdesivir for 5 or 10 days in patients with severe Covid-19 JD Goldman, DCB Lye, DS Hui, KM Marks, R Bruno, R Montejano, ... New England Journal of Medicine 383 (19), 1827-1837, 2020 | 1609 | 2020 |
| Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients PY Chia, KK Coleman, YK Tan, SWX Ong, M Gum, SK Lau, XF Lim, ... Nature communications 11 (1), 2800, 2020 | 960* | 2020 |
| Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B. 1.1. 7 (Alpha), B. 1.315 (Beta), and B. 1.617. 2 (Delta) SWX Ong, CJ Chiew, LW Ang, TM Mak, L Cui, MPHS Toh, YD Lim, ... | 492* | 2021 |
| Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study PY Chia, SWX Ong, CJ Chiew, LW Ang, JM Chavatte, TM Mak, L Cui, ... Clinical microbiology and infection 28 (4), 612. e1-612. e7, 2022 | 387 | 2022 |
| A neutralizing monoclonal antibody for hospitalized patients with Covid-19 Activ-3/Tico Ly-CoV555 Study Group New England Journal of Medicine 384 (10), 905-914, 2021 | 341 | 2021 |
| Connecting clusters of COVID-19: an epidemiological and serological investigation SEF Yong, DE Anderson, WE Wei, J Pang, WN Chia, CW Tan, YL Teoh, ... The Lancet infectious diseases 20 (7), 809-815, 2020 | 287 | 2020 |
| Imported Monkeypox, Singapore SEF Yong, OT Ng, ZJM Ho, TM Mak, K Marimuthu, S Vasoo, TW Yeo, ... Emerging infectious diseases 26 (8), 1826, 2020 | 270 | 2020 |
| Epidemiological and clinical predictors of COVID-19 Y Sun, V Koh, K Marimuthu, OT Ng, B Young, S Vasoo, M Chan, VJM Lee, ... Clinical Infectious Diseases 71 (15), 786-792, 2020 | 255 | 2020 |
| SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study OT Ng, K Marimuthu, V Koh, J Pang, KZ Linn, J Sun, L De Wang, WN Chia, ... The Lancet infectious diseases 21 (3), 333-343, 2021 | 251 | 2021 |
| Viral dynamics and immune correlates of coronavirus disease 2019 (COVID-19) severity BE Young, SWX Ong, LFP Ng, DE Anderson, WN Chia, PY Chia, LW Ang, ... Clinical Infectious Diseases 73 (9), e2932-e2942, 2021 | 198 | 2021 |
| Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a … SYC Tong, DC Lye, D Yahav, A Sud, JO Robinson, J Nelson, S Archuleta, ... Jama 323 (6), 527-537, 2020 | 184 | 2020 |
| SARS-CoV-2 infection among travelers returning from Wuhan, China OT Ng, K Marimuthu, PY Chia, V Koh, CJ Chiew, L De Wang, BE Young, ... New England Journal of Medicine 382 (15), 1476-1478, 2020 | 166 | 2020 |
| Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial AC Kalil, AK Mehta, TF Patterson, N Erdmann, CA Gomez, MK Jain, ... The lancet respiratory medicine 9 (12), 1365-1376, 2021 | 139 | 2021 |
| The novel coronavirus (SARS-CoV-2) pandemic LY Hsu, PY Chia, JF Lim Ann Acad Med Singap 49 (3), 105-7, 2020 | 130 | 2020 |
| Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised … WH Self, U Sandkovsky, CS Reilly, DM Vock, RL Gottlieb, M Mack, ... The Lancet Infectious Diseases 22 (5), 622-635, 2022 | 122 | 2022 |
